Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.
Marlys L Koschinsky, Archna Bajaj, Michael B Boffa, Dave L Dixon, Keith C Ferdinand, Samuel S Gidding, Edward A Gill, Terry A Jacobson, Erin D Michos, Maya S Safarova, Daniel E Soffer, Pam R Taub, Michael J Wilkinson, Don P Wilson, Christie M Ballantyne
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the relationship between lipoprotein(a) [Lp(a)] level and cardiovascular disease risk and risk reduction. Therefore, the NLA developed this focused update to guide clinicians in applying this emerging evidence in clinical practice. We now have sufficient evidence to support the recommendation to measure Lp(a) levels at least once in every adult for risk stratification...
March 29, 2024: Journal of Clinical Lipidology
#2
JOURNAL ARTICLE
Andrea E DeBarber, Ernst J Schaefer, Jenny Do, Joseph W Ray, Austin Larson, Samantha Redder, Maya Fowler, P Barton Duell
BACKGROUND: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid disorder. Affected patients often remain undiagnosed until the age of 20-30 years, when they have already developed significant neurologic disease that may not be reversible. An elevated plasma cholestanol concentration has been accepted as a diagnostic criterion for CTX for decades. OBJECTIVE: Full biochemical characterization was performed for three genetically and clinically confirmed atypical CTX cases with normal plasma cholestanol levels...
March 15, 2024: Journal of Clinical Lipidology
#3
EDITORIAL
Tyler J Schubert, Samuel S Gidding, Laney K Jones
Recent guidance by the United States Preventive Services Task Force has renewed the debate surrounding the benefits of pediatric lipid screening. This commentary reviews the evolution of the pediatric lipid screening recommendations in the United States, followed by an exploration of real and imagined challenges that prevent optimal cholesterol screening rates in children. Real challenges substantively prevent the uptake of these guidelines into practice; imagined challenges, such as identifying the best age to screen, are often context-dependent and can also be surmounted...
March 6, 2024: Journal of Clinical Lipidology
#4
JOURNAL ARTICLE
Banu Kadıoğlu Yılmaz, Halil Çelik
BACKGROUND: Cerebrotendinous xanthomatosis (CTX, OMIM #213700) is a rare but treatable lipid storage disease resulting from mutations in the CYP27A1 gene. PURPOSE: The study aims to evaluate patients diagnosed with CTX and reveal new information, especially about the signs of CTX and patients' response to the treatment. METHODS: The study was conducted retrospectively in 12 definitively diagnosed CTX patients. The patients' clinical, laboratory, imaging, genetic findings, and CDCA (chenodeoxycholic acid) treatment results were analyzed...
February 28, 2024: Journal of Clinical Lipidology
#5
JOURNAL ARTICLE
Simon-Pierre Guay, Martine Paquette, Amélie Taschereau, Véronique Desgagné, Luigi Bouchard, Sophie Bernard, Alexis Baass
BACKGROUND: Multifactorial chylomicronemia syndrome (MCS) is a severe form of hypertriglyceridemia associated with an increased risk of acute pancreatitis (AP). The risk of AP is heterogenous and is associated with increased level of triglycerides (TG) and presence of rare variants in TG metabolism-related genes. OBJECTIVE: To determine if the accumulation of common variants in pancreatitis susceptibility genes, measured with a weighted polygenic risk score (PRS), is associated with AP in MCS patients...
February 23, 2024: Journal of Clinical Lipidology
#6
JOURNAL ARTICLE
Karla Santo, Raul D Santos, Alysson Nathan Girotto, Josue Nieri, Frederico Monfardini, Priscila Raupp, Pedro Marton Pereira, Otavio Berwanger, M Julia Machline-Carrion
BACKGROUND: Statins consist of the main strategy to reduce dyslipidemia-related cardiovascular risk. Nevertheless, there is scarce evidence on the real-world statins use in primary care settings in low-middle-income countries. OBJECTIVE: We conducted a cross-sectional retrospective study using anonymized data routinely collected by community health workers in Brazil aimed to evaluate statin use and associated factors in a primary prevention population with cardiovascular risk enhancers...
February 20, 2024: Journal of Clinical Lipidology
#7
JOURNAL ARTICLE
Saleem Ansari, R Dermot G Neely, Jules Payne, Jaimini Cegla
Lipoprotein(a) is an independent risk factor for cardiovascular disease and its use is recommended in national and international guidelines for cardiovascular disease risk stratification. We undertook a survey to understand the availability and application of lipoprotein(a) measurement across UK lipid clinics. Fifty-three out of an estimated 200 lipid clinics (27%) provided responses. 81% of fifty-three clinics had access to lipoprotein(a) measurement. 27 clinics disclosed the number of lipoprotein(a) tests ordered annually with approximately half of the clinics (52%) requesting 0-250 tests per year...
February 15, 2024: Journal of Clinical Lipidology
#8
JOURNAL ARTICLE
Erin Zisman, Mian Hossain, Nicholas T Funderburg, Robert Christenson, Jean Jeudy, Shana Burrowes, Allison G Hays, Nivya George, Michael L Freeman, Heather Rebuck, Sarah E Mitchell, Michael Miller, Shashwatee Bagchi
BACKGROUND: Persons with HIV (PWH) have an increased risk of developing cardiovascular disease (CVD) compared to persons without HIV (PWoH). Lipoprotein a (Lp(a)) is a known atherosclerotic risk factor in PWoH, but there are no studies investigating Lp(a) and peri-coronary inflammation. OBJECTIVE: To investigate whether Lp(a) is associated with peri-coronary inflammation as assessed by the fat attenuation index (FAI) and activated monocytes and T lymphocytes in PWH and PWoH...
February 15, 2024: Journal of Clinical Lipidology
#9
JOURNAL ARTICLE
Sarah E Henson, Elaine M Urbina
BACKGROUND: Elevated lipid levels are risk factors for early atherosclerosis. Lipid ratios have emerged as potentially stronger predictors of adverse cardiovascular changes and atherogenic cholesterol. Risk stratification in youth with obesity or type 2 diabetes may be improved by using lipid ratios. We sought to determine if lipid ratios would identify abnormalities in arterial structure and stiffness in adolescents and young adults. METHODS: A total of 762 youth aged 10-24 years had laboratory, anthropometric, blood pressure, and carotid intima-media thickness and arterial stiffness data collected...
February 10, 2024: Journal of Clinical Lipidology
#10
JOURNAL ARTICLE
Raman Puri, Manish Bansal, Vimal Mehta, P Barton Duell, Nathan D Wong, S S Iyengar, Dinesh Kalra, Devaki R Nair, Navin C Nanda, Jagat Narula, P Deedwania, Jamal Yusuf, Jamshed J Dalal, Sadanand Shetty, Vinod M Vijan, Rajeev Agarwala, Soumitra Kumar, Kris Vijay, Aziz Khan, Gurpreet Singh Wander, P C Manoria, S K Wangnoo, Viswanathan Mohan, Shashank R Joshi, Balbir Singh, Prafulla Kerkar, Rajesh Rajput, D Prabhakar, Abdul Hamid Zargar, Banshi Saboo, Ravi R Kasliwal, Saumitra Ray, Sandeep Bansal, M U Rabbani, Shibba Takkar Chhabra, Sarat Chandra, Neil Bardoloi, Narasaraju Kavalipati, Immaneni Sathyamurthy, Kunal Mahajan, Akshya Pradhan, N N Khanna, Rajesh Khadgawat, Preeti Gupta, Milan C Chag, Ashu Gupta, A Murugnathan, S N Narasingan, Sundeep Upadhyaya, Vinod Mittal, Rashida Patanwala Melinkeri, Madhur Yadav, M Raseed Mubarak, K K Pareek, Pradeep Kumar Dabla, Rashmi Nanda, J C Mohan
OBJECTIVE: In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention of atherosclerotic cardiovascular disease (ASCVD) in Indians. The recent refinements in the role of various risk factors and subclinical atherosclerosis in prediction of ASCVD risk necessitated updating the risk algorithm and treatment goals. METHODS: The LAI core committee held twenty-one meetings and webinars from June 2022 to July 2023 with experts across India and critically reviewed the latest evidence regarding the strategies for ASCVD risk prediction and the benefits and modalities for intensive lipid lowering...
February 8, 2024: Journal of Clinical Lipidology
#11
JOURNAL ARTICLE
Pamela Piña, Daniel Lorenzatti, Francesco Castagna, Jeremy Miles, Toshiki Kuno, Andrea Scotti, Javier Arce, Ari Feinberg, Dou Huang, Jake Gilman, Ephraim Leiderman, Jonathan Daich, Paul Ippolito, Carlos A Gongora, Aldo L Schenone, Lili Zhang, Carlos J Rodriguez, Michael J Blaha, Damini Dey, Daniel S Berman, Salim S Virani, Jeffrey M Levsky, Mario J Garcia, Leandro Slipczuk
BACKGROUND: Coronary artery calcium (CAC), thoracic aorta calcification (TAC), non-alcoholic fatty liver disease (NAFLD), and epicardial adipose tissue (EAT) are associated with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF). OBJECTIVES: We aimed to determine whether these cardiometabolic and atherosclerotic risk factors identified by non-contrast chest computed tomography (CT) are associated with HF hospitalizations in patients with LDL-C≥ 190 mg/dL...
February 7, 2024: Journal of Clinical Lipidology
#12
JOURNAL ARTICLE
Tina Costacou, Rachel G Miller, Karin E Bornfeldt, Jay W Heinecke, Trevor J Orchard, Tomas Vaisar
BACKGROUND: In type 1 diabetes, women lose their relative protection (compared to men) against coronary artery disease (CAD), while HDL-C is less strongly associated with lower CAD risk in women. OBJECTIVE: We aimed to assess whether sex differences in the HDL particle concentration (HDL-P) and cholesterol efflux capacity (CEC) association with CAD may explain these findings. METHODS: HDL-P (calibrated differential ion mobility analysis) and total and ABCA1-specific CEC were quantified among 279 men and 271 women with type 1 diabetes (baseline mean age 27·8 years; diabetes duration, 19·6 years)...
January 29, 2024: Journal of Clinical Lipidology
#13
JOURNAL ARTICLE
Fotios Barkas, Christos V Rizos, George Liamis, Ioannis Skoumas, Anastasia Garoufi, Loukianos Rallidis, Genovefa Kolovou, Konstantinos Tziomalos, Emmanouil Skalidis, George Sfikas, Vasilios Kotsis, Michalis Doumas, Panagiotis Anagnostis, Vaia Lambadiari, Georgia Anastasiou, Iosif Koutagiar, Achilleas Attilakos, Estela Kiouri, Vana Kolovou, Georgios Polychronopoulos, Amalia-Despoina Koutsogianni, Evangelos Zacharis, Charalambos Koumaras, Christina Antza, Chrysoula Boutari, Evangelos Liberopoulos
BACKGROUND: Familial hypercholesterolemia (FH) and obesity are well-established risk factors of atherosclerotic cardiovascular disease (ASCVD). Despite high prevalence, their joint association with ASCVD remains largely unknown. OBJECTIVE: To investigate the association of obesity with prevalent ASCVD in individuals with heterozygous FH (HeFH) enrolled in the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). METHODS: FH diagnosis was based on Dutch Lipid Clinic Network (DLCN) criteria...
January 24, 2024: Journal of Clinical Lipidology
#14
JOURNAL ARTICLE
Zobaida Al-Baldawi, Leslie Brown, Isabelle Ruel, Alexis Baass, Jean Bergeron, Lubomira Cermakova, Patrick Couture, Daniel Gaudet, Gordon A Francis, Robert A Hegele, Iulia Iatan, G B John Mancini, Brian W McCrindle, Thomas Ransom, Mark H Sherman, Ruth McPherson, Jacques Genest, Liam R Brunham
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare, autosomal semi-dominant lipid metabolism disorder characterized by extremely high LDL-C levels and premature cardiovascular disease. The objective of this study was to investigate sex-differences in the treatment and outcomes of patients with HoFH. METHODS: We examined clinical characteristics, lipid-lowering therapy (LLT), and cardiovascular events using descriptive statistics of patients in the Canadian HoFH registry...
January 14, 2024: Journal of Clinical Lipidology
#15
JOURNAL ARTICLE
P Barton Duell, Maciej Banach, Alberico L Catapano, Ulrich Laufs, G B John Mancini, Kausik K Ray, Christine Broestl, Yang Zhang, Lei Lei, Anne C Goldberg
BACKGROUND: Patients with heterozygous familial hypercholesterolemia (HeFH) often cannot reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals despite multidrug therapy. OBJECTIVE: To evaluate the efficacy and safety of bempedoic acid as an add-on therapy for lowering LDL-C in patients with HeFH. METHODS: Pooled data from two 52-week phase 3 clinical trials of patients with atherosclerotic cardiovascular disease and/or HeFH receiving maximally tolerated statin therapy (randomized 2:1 to bempedoic acid or placebo) were analyzed by HeFH status...
January 11, 2024: Journal of Clinical Lipidology
#16
JOURNAL ARTICLE
Jihyun Yoon, Taehwa Han, Seok-Jae Heo, Yu-Jin Kwon
BACKGROUND: There remains a limited comprehensive understanding of how dyslipidemia and chronic inflammation collectively contribute to the development of CKD. OBJECTIVE: We aimed to identify clusters of individuals with five variables, including lipid profiles and C-reactive protein (CRP) levels, and to assess whether the clusters were associated with incident CKD risk. METHODS: We used the Korean Genome and Epidemiology Study-Ansan and Ansung data...
January 10, 2024: Journal of Clinical Lipidology
#17
JOURNAL ARTICLE
Laney K Jones, Katrina M Romagnoli, Tyler J Schubert, Katarina Clegg, H Lester Kirchner, Yirui Hu, Dylan Cawley, Victoria Norelli, Marc S Williams, Samuel S Gidding, Alanna K Rahm
BACKGROUND: We designed the Collaborative Approach to Reach Everyone with familial hypercholesterolemia (CARE-FH) clinical trial to improve FH screening in primary care and facilitate guideline-based care. OBJECTIVE: The goal was to incorporate perspectives from end-users (healthcare system leaders, primary care clinicians, cardiologists, genetic counselors, nurses, and clinic staff) and improve translation of screening guidance into practice. METHODS: We partnered with end-users to sequentially define the current state of FH screening, assess acceptability, feasibility, and appropriateness of implementing an FH screening program, and select clinically actionable strategies at the patient-, clinician-, and system-level to be deployed as a package in the CARE-FH clinical trial...
January 4, 2024: Journal of Clinical Lipidology
#18
EDITORIAL
Jonathan Q Purnell, Samuel A Camacho
No abstract text is available yet for this article.
2024: Journal of Clinical Lipidology
#19
EDITORIAL
Kevin C Maki, P Barton Duell
No abstract text is available yet for this article.
2024: Journal of Clinical Lipidology
#20
JOURNAL ARTICLE
Shannon Zoulek, Jackson Shriver, Navkiranjot Kaur, Beverly Kuznicki, Eric J Brandt
Since the COVID-19 pandemic, utilization of telemedicine visits has increased. The outcomes of virtual compared to face-to-face (F2F) visits for treating hyperlipidemia are uncharacterized. This observational study compared pre- to post-visit change in lipid markers between 41 virtual and 151 F2F visits with a registered dietitian nutritionist at the University of Michigan Preventive Cardiology program from 3/31/2019-9/31/2022. Total cholesterol (TC), high-density lipoprotein (HDL), and triglycerides (TG) were collected pre- and post-visit with a median 33 days between collections...
2024: Journal of Clinical Lipidology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
